Company intelligence / Profile preview

AIRAPSE

Cambridge, Massachusetts, United Statesairapse.com ↗

Ownership: Private
Development stage: Preclinical

Overview

AIRNA develops a proprietary RNA editing platform to create genetic medicines aimed at providing functional cures. Its lead program, AIR‑001, targets alpha‑1 antitrypsin deficiency by repairing mutations in the SERPINA1 gene. The company recently raised $155M Series B funding to support a Phase I/II trial of AIR‑001 and expand its pipeline into cardiometabolic and other diseases. No published clinical results yet; first-in-human studies are imminent or just starting.

Therapeutic areas: OtherCardiovascularRare Diseases
Modalities: RNA therapyGenetic medicine (RNA editing)
Industry: Biotech

Partnerships

Not specifically listed; major investors include Venrock Healthcare Capital Partners, Forbion Growth, Nextech Invest.

Beyond the preview

Go deeper on AIRAPSE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIRAPSE.

Explore the full profile